By Kamal Choudhury March 26 (Reuters) - Wave Life Sciences shares plunged 58% on Thursday after a higher dose of its experimental obesity drug failed to show a clear improvement at reducing a ...

Wave Life Sciences (WVE) fell ~57% in the premarket on Thursday as Wall Street reacted to interim data from an early-stage trial for WVE-007, its RNA-based obesity medicine. Citing six-month follow-up ...

Wave Life Sciences shares plunged >50% after Phase 1 INLIGHT data for WVE-007 showed <1% placebo-adjusted weight loss at six ...

In conversation with Fierce Pharma, Anthony Billinger, senior director of Compass Strategy at Veeva Systems, sheds light on the rapidly evolving world of commercial data in life sciences—and why the ...

Oracle announced the Oracle Life Sciences AI Data Platform, a generative AI-enabled solution designed to empower pharmaceutical, medical device, research, and life sciences organizations to accelerate ...

Veteran life sciences leader to drive enterprise growth and expand adoption of AI-ready data solutions across pharma and ...

Wave Life Sciences Ltd. WVE shares are tumbling on Thursday following the announcement of interim Phase 1 data from its ...

Management called the trial results “positive” mostly because the lower 240 mg dose of the WVE-007 injection helped ...

Leveraging Authentic Data for Life Science Breakthroughs. Reproducibility is one of the most urgent challenges in life ...

A surge of 147% in a single session is an unusual occurrence in biotech — and nearly unprecedented for a company that has spent years trading discreetly under the radar. However, that is precisely ...

Legend has it that physicist Ernest Rutherford once dismissed all sciences other than physics as mere “stamp collecting.” (Whether he actually said it is a matter of some debate.) But we now live in ...